Entries by canvax

Amal Therapeutics SA announces the appointment of Dr. Jean-Yves Bonnefoy as member of the Scientific Advisory Board

Geneva, Switzerland, April 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced the appointment of Jean-Yves Bonnefoy as new Scientific Advisory Board (SAB) member. Dr. Bonnefoy will bring over 20 years experience in Biotechnology company leadership and therapeutic cancer vaccine development. View PDF

Amal Therapeutics raises CHF 3 million in a Series A financing round

Geneva, Switzerland, and Ingelheim, Germany, March 30, 2016 – Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. View PDF

US Patent granted for Amal Therapeutics’ novel cancer vaccine technology platform

GENEVA, December 1, 2015 – Amal Therapeutics SA (“Amal”), a biotechnology company developing active immunotherapies, announced the issuance on November 17, 2015 of the US Patent number 9,187,534 entitled “MULTI-EPITOPIC VACCINE” by the US Patent and Trademark Office (USPTO). This patent covers Amal’s multi-epitopic vaccine technology platform and its use as immunotherapy for the treatment […]

Amal Therapeutics and the Oslo University Hospital announce research collaboration agreement for cancer immunotherapy validation

Geneva, Switzerland, September 8, 2015 – Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional […]

Amal Therapeutics to publish R&D findings in Cancer Research

Geneva, Switzerland, June 26, 2015 – Amal Therapeutics announced today that part of its recent research findings about a new type of recombinant protein cancer vaccines, will be available on-line on the Cancer Research website on Friday June 26, 2015. View PDF

Amal Therapeutics awarded with CTI Start-up Label

Geneva, Switzerland, November 26, 2014 – Amal Therapeutics, a Geneva based start-up biotech company developing and progressing therapeutic vaccines in oncology, announced today that it received the CTI Start-up Label from Swiss Commission for Technology and Innovation (CTI). This recognition of a promising development places Amal Therapeutics into the selective group of CTI certified Swiss […]

Amal Therapeutics receives EU funding for the development of a new glioblastoma vaccine

24 July 2014, Geneva, Switzerland and Archamps, France – Amal Therapeutics, a Swiss biotech start-up company, and TransCure bioServices, a French preclinical contract research organization, have obtained a European Eurostars Programme grant, for a total of 1.07 million Euro. This award winning project, named HuVac, aims to use enhanced humanized immune system mouse models for […]